RecruitingNCT07390617

A Study of Neuropathy Caused by Enfortumab Vedotin in People With Urothelial Carcinoma

Interrogating Enfortumab Vedotin-associated Neuropathy in Patients With Metastatic or Muscle-Invasive Urothelial Carcinoma Receiving Enfortumab Vedotin

Sponsor

Memorial Sloan Kettering Cancer Center

Enrollment

50 participants

Start Date

Jan 20, 2026

Study Type

OBSERVATIONAL

Conditions

Urothelial Carcinoma Metastatic Urothelial Carcinoma Neuropathy

Summary

The purpose of this study is to see how results of nerve tests change in people with urothelial cancer who receive treatment with enfortumab vedotin (EV)

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Non-therapeutic Nerve Conduction Studies and Non-therapeutic assessment of patient-reported neuropathy for people with metastatic urothelial carcinoma, neuropathy, and other related conditions. The study is currently recruiting participants at 7 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERNon-therapeutic Nerve Conduction Studies

Non-invasive nerve conduction studies (NCS) offer an objective, quantitative approach to assess peripheral nerve function, particularly in sensory fibers, which are most commonly affected in chemotherapy-induced peripheral neuropathy/CIPN

OTHERNon-therapeutic assessment of patient-reported neuropathy

To evaluate the incidence and severity of chemotherapy-induced peripheral neuropathy (CIPN) in participants receiving enfortumab vedotin, we will collect non-therapeutic, participant-reported outcomes